COMPARISON OF 550MG/DAY VERSES 1100 MG/DAY RIFAXIMIN IN SECONDARY PREVENTION OF BOTH COVERT AND OVERT HEPATIC ENCEPHALOPATHY

N BIBI; MA MALIK

doi:10.54112/pjicm.v5i01.71

Authors

N BIBI Department of Medicine, Sheikh Zayed Hospital, Rahim Yar Khan, Pakistan
MA MALIK Department of Medicine, Sheikh Zayed Hospital, Rahim Yar Khan, Pakistan

DOI:

https://doi.org/10.54112/pjicm.v5i01.71

Keywords:

Hepatic Encephalopathy, Rifaximin, Covert HE, Overt HE, Secondary Prevention, Recurrence, Cirrhosis

Abstract

Hepatic encephalopathy (HE) is a serious complication of liver cirrhosis, presenting in covert and overt forms, and often recurs after initial treatment. Rifaximin, a non-absorbable antibiotic, is widely used for secondary prevention, but the optimal dose for preventing HE recurrence remains uncertain. Objective: To compare the frequency of recurrence of both covert and overt hepatic encephalopathy in patient taking rifaximin at 550mg/day verses 1100mg/day. Study Design: Randomized, controlled, comparative study. Setting: Department of Medicine, Sheikh Zayed Hospital, Rahim Yar Khan, Pakistan. Duration of Study: Six months, from September 6, 2024, to March 6, 2025. Methods: A total of 160 patients diagnosed with either covert or overt HE were enrolled and randomized into two treatment groups via block randomization. Group A received 550 mg/day rifaximin, and Group B received 1100 mg/day. The primary outcome was the frequency of HE recurrence over the study period. Statistical analysis was performed using SPSS version 26. Chi-square test was applied to compare recurrence rates between groups, with p < 0.05 considered statistically significant. Results: In Group A, 47.5% of patients experienced recurrence of HE, compared to 43.8% in Group B. The difference in recurrence rates between the two groups was not statistically significant (p = 0.63). Conclusion: There was no significant difference in the efficacy of 550 mg/day versus 1100 mg/day rifaximin in preventing HE recurrence. Given the comparable outcomes, the standard 550 mg/day dose remains the preferred regimen for secondary prevention of hepatic encephalopathy due to its effectiveness and potential cost-benefit advantage.

References

Nabi E, Thacker LR, Wade JB, Sterling RK, Stravitz RT, Fuchs M, et al. Diagnosis of covert hepatic encephalopathy without specialized tests. Clin Gastroenterol Hepatol. 2014;12(8):1384-9.

Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-37.

American Association for the Study of Liver Diseases. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61(3):642-59.

Vilstrup H, Amodio P, Bajaj J. AASLD Practice guideline hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology.2014; 60(2):715-35.

Jaffe A, Lim JK, Jakab SS. Pathophysiology of hepatic encephalopathy. Clin Liver Dis. 2020;24(2):175-88.

Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, et al. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol. 2020;73(6):1526-47.

Jin X, Chen D, Wu F, Zhang L, Huang Y, Lin Z, et al. Hydrogen sulfide protects against ammonia-induced neurotoxicity through activation of Nrf2/ARE signaling in astrocytic model of hepatic encephalopathy. Front Cell Neurosci. 2020;14:573422.

Montagnese S, Rautou PE, Romero-Gómez M, Larsen FS, Shawcross DL, Thabut D, et al. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807-24.

Tapper EB, Parikh ND, Sengupta N, Mellinger J, Ratz D, Lok AS, et al. A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. Hepatology. 2018;68(4):1498-1507.

Orman ES, Roberts A, Ghabril M, Nephew L, Desai AP, Patidar K, et al. Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis. JAMA Netw Open. 2019;2(6):e196412.

Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-81.

Tan W, Wang J, Shi PM, Feng LM, Shi J, Ning BF, et al. Effects of low-dose and high-dose Rifaximin in the treatment of Covert hepatic encephalopathy. J Clin Transl Hepatol. 2022;10(6):1099.

Khokhar N, Qureshi MO, Ahmad S, Ahmad A, Khan HH, Shafqat F, Salih M. Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease. J Gastroenterol Hepatol. 2015;30(9):1420-1422.

Perrone V, Usala M, Veronesi C, Cappuccilli M, Degli Esposti L. Drug utilization of rifaximin-α in patients with hepatic encephalopathy: Evidence from real clinical practice in Italy. Medicina. 2025;61(2):221.

Sarwar S, Muhyuddin B, Aleem A, Nadeem MA. Primary prophylaxis of hepatic encephalopathy in decompensated cirrhosis: Low dose vs. full dose rifaximin. Pak J Med Sci. 2019;35(5):1446-1450.

Habib N, Amjad M, Afzal M, Iqbal MZ, Shehzad MA. Compare the efficacy of low versus high dose of rifaximin for primary prophylaxis of protosystemic encephalopathy. P J M H S. 2020;14(3):843-845